Edition:
India

Bio Path Holdings Inc (BPTH.OQ)

BPTH.OQ on NASDAQ Stock Exchange Capital Market

0.23USD
2:29am IST
Change (% chg)

$0.00 (+0.26%)
Prev Close
$0.23
Open
$0.23
Day's High
$0.25
Day's Low
$0.22
Volume
260,103
Avg. Vol
111,857
52-wk High
$1.37
52-wk Low
$0.19

Summary

Name Age Since Current Position

Peter Nielsen

67 Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer

Ulrich Mueller

50 2017 Secretary

Douglas Morris

78 2014 Director

Heath Cleaver

43 2014 Independent Director

Mark Colonnese

61 2017 Independent Director

Biographies

Name Description

Peter Nielsen

Mr. Peter Henry Nielsen is a Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer of the Company, Mr. Nielsen co-founded Bio-Path and has served as Bio-Path’s President, Chief Executive Officer, Chief Financial Officer/Treasurer and Chairman of the Board since 2008. At the time of Bio-Path’s establishment in 2007, Mr. Nielsen licensed technology and targets from The University of Texas, MD Anderson Cancer Center and coordinated pre-clinical development, optimization and manufacturing of Bio-Path’s lead drug candidate, BP1001. Over the next nine years, Mr. Nielsen led the clinical advancement of BP1001 into Phase II studies, the introduction of additional pipeline candidates and the Company’s public market debut. Prior to co-founding Bio-Path, Mr. Nielsen worked with several other companies, leading turnarounds and developing and executing on strategies for growth. In addition to his service as a director of Bio-Path, Mr. Nielsen currently serves as a director of Synthecon, Inc., a company developing 3D cell culture technology. Before entering the biotechnology sector, Mr. Nielsen was a lieutenant in the U.S. Naval Nuclear Power program where he was director of the physics department and was employed at Ford Motor Company in product development. Mr. Nielsen has a broad background in senior management and has significant negotiating experience. He holds engineering, mathematics and M.B.A. finance degrees from the University of California at Berkeley.

Ulrich Mueller

Dr. Ulrich W. Mueller, Ph.D, is Secretary of the Company. Dr. Mueller has served as Bio-Path’s Chief Operating Officer and Secretary since March 2014. Between 2007 and 2014, Dr. Mueller managed various administrative departments at Fred Hutchinson Cancer Research Center, a leading research center for cancer and other life-threatening diseases. Dr. Mueller most recently served as Fred Hutchinson Cancer Research Center’s Vice President, Industry Relations and Clinical Research Support. Between 2000 and 2007, Dr. Mueller served in various capacities at MD Anderson, including as Managing Director, Director of Licensing, and Assistant Director of Business Development. Dr. Mueller holds a Ph.D. in Cell and Molecular Biology from Baylor College of Medicine, a Master’s degree in Biology from Texas A&M University, and a Bachelor of Science in Microbiology from New Mexico State University.

Douglas Morris

Mr. Douglas P. Morris is a Director of the Company. Mr. Morris is a co-founder of Bio-Path and has served as a director of Bio-Path since 2007 and served as an officer from 2007 to June 2014. Mr. Morris currently serves as Director of Investment Relations of Bio-Path. Mr. Morris previously served as a co-founder, Managing Member, and Secretary of nCAP Holdings, LLC (nCAP), a privately held technology based company from September 2013 to January 2016. Between 1993 and 2010, Mr. Morris was an officer and director of Celtic Investment, Inc., a financial services company. Mr. Morris has owned and operated Hyacinth Resources, LLC (“Hyacinth”), a business-consulting firm since 1990 and is also a Managing Member of Sycamore Ventures, LLC, a privately held consulting firm. Mr. Morris has a B.A. from Brigham Young University, and attended the University of Southern California Masters program in public administration.

Heath Cleaver

Mr. Heath W. Cleaver, CPA is an Independent Director of the Company. Mr. Cleaver has served as a director of Bio-Path since February 2014. Mr. Cleaver is currently a consultant providing turn-around management and capital raising services to companies in the oil and gas service sector. From 2015 to 2016, Mr. Cleaver served as the Chief Financial Officer of Global Fabrication Services, Inc. In 2014, Mr. Cleaver served as Chief Financial Officer at Tarka Resources, Inc. From 2011 until 2014, Mr. Cleaver served as Chief Financial Officer of Porto Energy Corp. From 2010 until 2011, Mr. Cleaver served as Chief Accounting Officer of Porto Energy Corp. Mr. Cleaver served as Corporate Controller and then as Vice President and Chief Accounting Officer for BPZ Energy from 2006 to 2010. Beginning in 1997 through 2004, Mr. Cleaver served in various accounting roles, including Financial Controller, at Horizon Offshore Contractors, Inc. Mr. Cleaver is a Certified Public Accountant in the state of Texas and holds a Bachelor's Degree in Business Administration - Accounting from Texas A&M University.

Mark Colonnese

Mr. Mark P. Colonnese serves as Independent Director of the company. Mr. Colonnese brings over 30 years of broad executive management skills and financial experience at Fortune 500 as well as small entrepreneurial companies. He currently serves as the Executive Vice President and Chief Financial Officer of Aviragen Therapeutics, Inc., a NASDAQ-listed antiviral drug development company. Earlier in his career, Mr. Colonnese was chief financial officer at a number of biotechnology companies including Stealth BioTherapeutics, Transgenomic Inc., and AtheroGenics Inc. Mr. Colonnese also served as Vice President, Financial Operations at Schering-Plough Corporation, now part of Merck, one of the world’s largest pharmaceutical companies. In these roles, he was responsible for raising $870 million in equity and debt capital, as well as $100 million from partnerships, and directing two companies through their initial public offerings. Mr. Colonnese holds a Master of Business Administration from Fairleigh Dickinson University and a Bachelor of Science, magna cum laude from Ithaca College.

Basic Compensation

Name Fiscal Year Total

Peter Nielsen

475,000

Ulrich Mueller

489,253

Douglas Morris

52,000

Heath Cleaver

--

Mark Colonnese

--
As Of  31 Dec 2015

Options Compensation